Abstract: The present disclosure relates to an external device-to-external device connector for wireless communication devices, which is configured to electrically connect two spaced external devices together, and comprises two interface members and a coupling member. The inner conductor part and the insulation part of the coupling member are held together by the concave-convex fitting parts opposite to each other, and there is a first gap between the concave-convex fitting part of the inner conductor part and that of the insulation part, which allows the inner conductor part to have radial displacement relative to the insulation part; or, the outer conductor part and the insulating part of the coupling member are held together by the concave-convex fitting parts opposite to each other, and there is a second gap between the concave-convex fitting part of the outer conductor part and that of the insulating part, which allows radial displacement of the insulating part relative to the outer conductor part.

Abstract: An integrated high-precision weighing module is provided which includes a scale pan, a lever, an internal calibration system, a bottom plate assembly, and a sensor main body. The scale pan is mounted on the lever, and the lever is connected to the sensor main body. The internal calibration system, the sensor main body and the lever are arranged transversely, and the internal calibration system and the sensor main body are respectively attached to the bottom plate assembly.

Abstract: In certain aspects, a three-dimensional (3D) memory device includes a stack structure including interleaved conductive layers and dielectric layers and having a core array region and a staircase region in a plan view, one or more channel structures each extending through the core array region of the stack structure, and one or more contact structures each extending through the stack structure, wherein each of the one or more contact structures includes a head portion and a body portion, and a width of the head portion of the respective contact structure is larger than that of the body portion of the respective contact structure.

Abstract: An intelligent plate parts machining production line combining universal equipment and special equipment. Four special machining tools are located on first to fourth stations, respectively, and a universal machining tool is located on a fifth station. The stations are sequential from an automatic feeding device. Truss conveying devices are behind the first to fourth stations, and four mechanical arms are on the truss conveying devices. A four-axis manipulator is between the fourth and fifth stations for transferring materials between the two stations and discharging finished products. Industrial cameras are on the second-station mechanical arm and the four-axis manipulator. Waste boxes are between the first and second stations and between the fourth and fifth stations. A discharging box is on the front side of the fifth station. A scrap conveying mechanism is below the production line. Flexible clamps and sliding rail cylinders are used, so that the production line is flexible.

Abstract: An intelligent plate parts machining production line combining universal equipment and special equipment. Four special machining tools are located on first to fourth stations, respectively, and a universal machining tool is located on a fifth station. The stations are sequential from an automatic feeding device. Truss conveying devices are behind the first to fourth stations, and four mechanical arms are on the truss conveying devices. A four-axis manipulator is between the fourth and fifth stations for transferring materials between the two stations and discharging finished products. Industrial cameras are on the second-station mechanical arm and the four-axis manipulator. Waste boxes are between the first and second stations and between the fourth and fifth stations. A discharging box is on the front side of the fifth station. A scrap conveying mechanism is below the production line. Flexible clamps and sliding rail cylinders are used, so that the production line is flexible.

Abstract: Disclosed arc compositions, methods, and kits for treating a solid tumor comprising co- administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor: a taxane, or an EGFR inhibitor.

Abstract: Disclosed are compositions, methods, and kits for treating a solid tumor comprising co-administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor; a taxane, or an EGFR inhibitor.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudo-virus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudo-viruses (VLPs with plasmids inside). Oral administration of the pseudo-viruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudo-virus induces stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It characterizes that: the HPV or BPV pseudo-virus made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), reassembled into pseudo-virus (VLPs with plasmids inside). The pseudo-virus can be orally given, entering mucosa and systemic lymphoid tissues of human body, activate immune system and serve as treating and preventing agent. The pseudo-virus can induce stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in human body.